Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zonisamide for Weight Reduction in Obese Adults.

Trial Profile

Zonisamide for Weight Reduction in Obese Adults.

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Zonisamide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Aug 2013 Results published in JAMA: the Journal of the American Medical Association.
    • 12 Nov 2012 Primary endpoint 'Bodyweight-reduction' has been met for 400 mg/day dosage, according to results in the Archives of Internal Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top